Related Experiment Videos
[Benign prostatic hyperplasia]. Summary This summary is machine-generated. Benign prostatic hyperplasia (BPH) involves stromal tissue changes and requires ultrasound for accurate size assessment. Current treatments are symptomatic, with transurethral prostatectomy being a common surgical option for BPH symptoms.
You might also read
Related Articles Articles linked to this work by shared authors, journal, and citation graph.
Laparoscopic donor nephrectomy. Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy · 2006
Area of Science:
Urology Pathomorphogenesis Medical Diagnostics Context:
The exact causes of benign prostatic hyperplasia (BPH) remain unclear, despite ongoing research. Fibromuscular (stromal) tissue plays a significant role in BPH pathomorphogenesis, with a relative decrease in glanduloparenchymal area observed. Understanding the underlying mechanisms of BPH is crucial for developing effective diagnostic and therapeutic strategies. Purpose:
To review the current understanding of benign prostatic hyperplasia (BPH) etiology and pathomorphogenesis. To highlight key diagnostic methods, including urine flow measurement and ultrasound for prostate sizing. To discuss current therapeutic limitations and surgical interventions for symptomatic BPH. Summary:
Benign prostatic hyperplasia (BPH) pathogenesis involves significant changes in stromal tissue.
Related Experiment Videos
Urine flow measurement is a critical screening tool, while ultrasound is essential for accurate presurgical prostate size determination.
Hydrodynamic effects on the bladder can be assessed using combined flow and pressure measurements.
Current pharmacological treatments for BPH are purely symptomatic, lacking causative action.
Transurethral prostatectomy is the primary surgical option for managing symptomatic BPH.
Postoperative complications, such as strictures and stones, require thorough investigation. Impact:
Improved diagnostic accuracy through validated screening and imaging techniques. Informed clinical decision-making regarding symptomatic BPH management. Highlights the need for causative pharmacotherapy development for benign prostatic hyperplasia (BPH).